The preliminary finding means some antibody therapies on the market may need to be tweaked if omicron becomes widespread, according to The Wall Street Journal..
Past computer modeling and laboratory research involving several mutations present in omicron show that there may be reduced neutralization activity against the variant, Regeneron said. The drugmaker said it expects to have a better sense of exactly how omicron affects the antibody therapy within a few weeks, after further research using omicron’s full sequence is complete.
If testing confirms that the antibody therapy is less effective, Regeneron said it’s already been testing other antibody drug candidates, some of which “may have the potential to retain activity against the omicron variant.” The company plans to share more data from these analyses in the next month.
To learn more, click here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
